Related Experiment Videos

[Monotherapy of Pseudomonas aeruginosa septicemia with azlocillin]

Presse Medicale (Paris, France : 1983)
|March 29, 1984
PubMed

Insights

Azlocillin effectively treated Pseudomonas aeruginosa sepsis in most surgical patients. However, one patient developed resistance and died from multivisceral failure, highlighting treatment challenges.

Area of Science:

  • Pharmacology
  • Infectious Diseases
  • Critical Care Medicine

Background:

  • Pseudomonas aeruginosa is a significant cause of post-surgical infections, often leading to severe complications like shock and renal failure.
  • Antibiotic resistance, particularly to carbenicillin, is a growing concern in managing P. aeruginosa infections.

Observation:

  • Seven patients with P. aeruginosa septicaemia, primarily post-surgery, were treated with azlocillin.
  • Three patients experienced shock, with two cases complicated by acute anuric renal failure.
  • Azlocillin minimum inhibitory concentrations ranged from 2 to 32 µg/ml; five strains showed carbenicillin resistance.

Findings:

  • Bacterial eradication was achieved in six out of seven patients treated with azlocillin.
  • The minimum inhibitory to minimum bactericidal concentration ratio for azlocillin was consistently 2.
  • One patient with multivisceral failure succumbed to the infection after the organism developed azlocillin resistance.

Implications:

  • Azlocillin demonstrates significant efficacy in treating P. aeruginosa septicaemia, especially in post-surgical settings.
  • The emergence of azlocillin resistance in a critical case underscores the need for vigilant monitoring and alternative therapeutic strategies.
  • This study highlights the importance of considering antibiotic resistance patterns in Pseudomonas aeruginosa infections and tailoring treatment accordingly.

Related Concept Videos